Literature DB >> 28090573

Nuclear reprogramming of cancer stem cells: Corrupting the epigenetic code of cell identity with oncometabolites.

Javier A Menendez1, Tomás Alarcón2.   

Abstract

Generation of cancer stem cell (CSC)-like cells might occur through metabolic corruption of the epigenetic codes that govern cell identity. We recently identified how archetypal oncometabolites, without altering the baseline expression of endogenous stem cell maintenance genes but endowing cells with epigenetic states refractory to differentiation, considerably enhance the global kinetic efficiency of nuclear reprogramming processes that generate CSC-like states de novo. This study highlights that metabolo-epigenetic axes of communication can direct the development and maintenance of CSCs during the natural history of cancer diseases.

Entities:  

Keywords:  Cancer stem cells; epigenetics; nuclear reprogramming; oncometabolites

Year:  2016        PMID: 28090573      PMCID: PMC5160399          DOI: 10.1080/23723556.2016.1160854

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN: 2372-3556


  10 in total

Review 1.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.

Authors:  Patrick S Ward; Craig B Thompson
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

2.  Metabolic regulation of epigenetics.

Authors:  Chao Lu; Craig B Thompson
Journal:  Cell Metab       Date:  2012-07-03       Impact factor: 27.287

3.  Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.

Authors:  Kotaro Ohnishi; Katsunori Semi; Takuya Yamamoto; Masahito Shimizu; Akito Tanaka; Kanae Mitsunaga; Keisuke Okita; Kenji Osafune; Yuko Arioka; Toshiyuki Maeda; Hidenobu Soejima; Hisataka Moriwaki; Shinya Yamanaka; Knut Woltjen; Yasuhiro Yamada
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

4.  Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells.

Authors:  Nobuaki Shiraki; Yasuko Shiraki; Tomonori Tsuyama; Fumiaki Obata; Masayuki Miura; Genta Nagae; Hiroyuki Aburatani; Kazuhiko Kume; Fumio Endo; Shoen Kume
Journal:  Cell Metab       Date:  2014-04-17       Impact factor: 27.287

Review 5.  Metabolic Reprogramming of Stem Cell Epigenetics.

Authors:  James G Ryall; Tim Cliff; Stephen Dalton; Vittorio Sartorelli
Journal:  Cell Stem Cell       Date:  2015-12-03       Impact factor: 24.633

Review 6.  Metabostemness: a new cancer hallmark.

Authors:  Javier A Menendez; Tomás Alarcón
Journal:  Front Oncol       Date:  2014-09-29       Impact factor: 6.244

7.  Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions.

Authors:  Javier A Menendez; Bruna Corominas-Faja; Elisabet Cuyàs; Tomás Alarcón
Journal:  Oncoscience       Date:  2014-12-26

8.  Oncometabolic Nuclear Reprogramming of Cancer Stemness.

Authors:  Javier A Menendez; Bruna Corominas-Faja; Elisabet Cuyàs; María G García; Salvador Fernández-Arroyo; Agustín F Fernández; Jorge Joven; Mario F Fraga; Tomás Alarcón
Journal:  Stem Cell Reports       Date:  2016-02-11       Impact factor: 7.765

9.  Influence of threonine metabolism on S-adenosylmethionine and histone methylation.

Authors:  Ng Shyh-Chang; Jason W Locasale; Costas A Lyssiotis; Yuxiang Zheng; Ren Yi Teo; Sutheera Ratanasirintrawoot; Jin Zhang; Tamer Onder; Juli J Unternaehrer; Hao Zhu; John M Asara; George Q Daley; Lewis C Cantley
Journal:  Science       Date:  2012-11-01       Impact factor: 47.728

10.  Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells.

Authors:  Bryce W Carey; Lydia W S Finley; Justin R Cross; C David Allis; Craig B Thompson
Journal:  Nature       Date:  2014-12-10       Impact factor: 49.962

  10 in total
  2 in total

1.  Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer.

Authors:  Javier A Menendez; Tomás Alarcón
Journal:  Front Cell Dev Biol       Date:  2017-05-05

2.  Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity.

Authors:  Elisabet Cuyàs; Sara Verdura; Salvador Fernández-Arroyo; Joaquim Bosch-Barrera; Begoña Martin-Castillo; Jorge Joven; Javier A Menendez
Journal:  Oncotarget       Date:  2017-10-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.